Long-Term Effectiveness and Safety of Abrocitinib in Patients with Atopic Dermatitis: A Real-World, Retrospective Study - PubMed
4 days ago
- #Abrocitinib
- #Atopic Dermatitis
- #Real-World Study
- Abrocitinib is highly effective for treating atopic dermatitis (AD) based on a 2-year real-world study.
- The study included 23 patients with moderate-to-severe AD, showing significant improvements in EASI and SCORAD scores from baseline to week 104.
- Patient-reported outcomes, including quality of life (QoL) and itch severity, improved significantly, with 61% achieving DLQI < 2 and 83% achieving WP-NRS 0/1.
- Abrocitinib demonstrated a favorable safety profile, with only 13% of patients discontinuing due to adverse events (AEs), most of which were mild.
- The findings align with clinical trial data, supporting abrocitinib's long-term effectiveness and safety in AD management.